Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 67

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 67
---
     | Number of SecuritiesUnderlying the Award |     |           |     | ExercisePrice ofthe Award(s) |     |        |     | Grant DateFair Valueof theAward 
 ($)(1)                          |     |           |     | Percentage Change inthe Closing Market Priceof the SecuritiesUnderlying the AwardBetween the Trading DayEnding ImmediatelyPrior to the Disclosure ofMaterial NonpublicInformation and theTrading Day BeginningImmediately Followingthe Disclosure ofMaterial Nonpublic 
 Information                                                                                                                                                                                                                                                            |     |    |
| Jayson Rieger        |     |            |     | 11/06/2024 |     |                                          |     | 2,000,000 |     |                              |     | 0.7463 |     |                                 |     | 1,187,744 |     |                                                                                                                                                                                                                                                                        |     | -2 |
| Christopher G. Hayes |     |            |     | 10/09/2024 |     |                                          |     |    50,000 |     |                              |     |   1.28 |     |                                 |     |    50,500 |     |                                                                                                                                                                                                                                                                        |     | -3 |

| (1) | The amounts reflect the full grant date fair value, computed in accordance with ASC Topic 718. Consistent with the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 8 to our audited financial statements included in our Annual Report on Form10-Kfor the year ended December 31, 2024. |

| (2) | We filed our Quarterly Report on Form10-Qfor the quarter ended September 30, 2024pre-marketon November 5, 2024. The closing stock price per share of our common stock on November 4, 2024 and November 6, 2024 was $1.43 and $0.7463, respectively. |

| (3) | We filed a Current Report on Form8-Kafter market close on October 8, 2024. The closing stock price per share of our common on each of October 8, 2024 and October 9, 2024 was $1.28. |

48

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS The